Skip to main content
BioInfra Co.,Ltd. logo

BioInfra Co.,Ltd. — Investor Relations & Filings

Ticker · 199730 ISIN · KR7199730003 KO Professional, scientific and technical activities
Open in API
Filings indexed 88 across all filing types
Latest filing 2023-02-17 Capital/Financing Update
Country KR South Korea
Listing KO 199730

About BioInfra Co.,Ltd.

http://bioinfra.co.kr/?lang=en

BioInfra Co., Ltd. is a biotechnology and healthcare company specializing in innovative solutions for disease prevention and early detection, with a primary focus on oncology. The company's core technology is a proprietary multi-biomarker blood test for the early screening of eight major cancers, including lung, liver, stomach, colorectal, prostate, breast, pancreatic, and ovarian cancer. This in vitro diagnostic tool analyzes a small blood sample to assess cancer risk, aiming to improve patient outcomes through early intervention. Beyond diagnostics, BioInfra also engages in pharmaceutical research and development, offering clinical research services and developing cancer gene treatments.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by Bioinfra Co., Ltd. It contains detailed information regarding the public offering of shares, including demand forecasting results, pricing, and investment risk factors. This is a formal regulatory filing required for public offerings in South Korea, which falls under the category of a Securities Registration Statement. Given the provided options, this document is best classified as a Regulatory Filing (RNS) as it is a formal legal filing with the financial regulator.
2023-02-17 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 95% confidence The document is a 'Investment Prospectus' (투자설명서) for BioInfra Co., Ltd., which includes detailed information about the company's business, risk factors, and public offering details. It is a formal regulatory filing submitted to the Financial Supervisory Service (FSS) in South Korea. While it contains financial data, it is not an Annual Report (10-K) or an Interim Report (IR), but rather a specific document related to a securities offering. In the context of the provided categories, this fits best as a Regulatory Filing (RNS) as it is a formal, mandatory disclosure document for a public offering that does not fall into the other specific categories like 'SHA' (Share Issue) or 'IP' (Investor Presentation).
2023-02-17 Korean
투자설명서
Capital/Financing Update Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) for BioInfra Co., Ltd., dated February 14, 2023. It details the offering of 650,000 common shares, including the offering price range, subscription period, and payment dates. It also contains extensive sections on investment risks, business overview, and financial information required for a public offering (IPO). This document is a formal regulatory filing for a securities offering, which falls under the 'Proxy Solicitation & Information Statement' category in the provided schema, as it serves as the primary disclosure document for investors to make informed decisions during a public offering.
2023-02-14 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Amendment to Securities Registration Statement) filed by Bioinfra. It explicitly states it is a correction to a previously submitted securities registration statement, detailing specific changes in management, research personnel, and offering schedules. This type of regulatory filing for securities registration is classified under 'Regulatory Filings' (RNS) as it is a formal amendment to a regulatory document.
2023-01-25 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details the company's intent to offer shares (IPO), provides investment risk factors, financial summaries, and information regarding the offering process. This document is a formal regulatory filing required for public offerings of securities.
2023-01-19 Korean
철회신고서
Capital/Financing Update Classification · 95% confidence The document is a '철회신고서' (Withdrawal Statement) filed with the Financial Services Commission (금융위원회) by Bioinfra Co., Ltd. It explicitly states the company is cancelling its public offering (공모) due to market conditions and the inability to properly evaluate the company's value. Since this is a regulatory filing regarding the cancellation of a securities offering and does not fit into specific categories like M&A or dividend announcements, it falls under the general regulatory filing category.
2022-11-21 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.